Science News

... from universities, journals, and other research organizations

Researchers Identify Unique Immune Gene Signature Across Thousands of Patients' Solid Tumors

Oct. 25, 2012 — Researchers at Moffitt Cancer Center have discovered a unique immune gene signature that can predict the presence of microscopic lymph node-like structures in metastatic melanoma. The presence of these immune structures, the researchers said, appears to be associated with better survival and may indicate the possibility of selecting patients for immunotherapy based solely on the immune-related makeup of their tumors as an approach to personalized medicine.


Share This:

The study appears in Scientific Reports, a journal from Nature Publishing Group.

In this study, the researchers analyzed a 12-chemokine gene expression signature across nearly 15,000 distinct solid tumors of different types, including metastatic melanoma. Chemokines are powerful immune system molecules known to be important in lymph node formation and function during development. The 12-chemokine gene expression signature was found to remarkably predict the presence of microscopic lymph node-like structures within some melanomas and was also associated with better overall survival of these patients.

The researchers speculate that the lymph nodal structures they identified are active and playing an important positive role in a self-elicited (endogenous) anti-tumor response -- initially locally and then systemically. They also anticipate that their findings in melanoma may extend to other solid tumors, such as those of colorectal, lung and ovarian origin.

"We believe this gene expression signature reveals information on a unique anti-tumor response mechanism within the microenvironment of certain patient solid tumors, which may be their Achilles' heel to make them unusually responsive to immunotherapy and possibly lead to improved patient survival," explained the study's senior author, James J. Mulé, Ph.D., associate center director of Translational Research at Moffitt.

This study was supported in part by the National Cancer Institute, part of the National Institutes of Health (R01 CA148995), The V Foundation for Cancer Research and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. This work also utilized the Total Cancer Care® biorepository and data warehouse.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by H. Lee Moffitt Cancer Center & Research Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Jane L. Messina, David A. Fenstermacher, Steven Eschrich, Xiaotao Qu, Anders E. Berglund, Mark C. Lloyd, Michael J. Schell, Vernon K. Sondak, Jeffrey S. Weber, James J. Mul. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? Scientific Reports, 2012; 2 DOI: 10.1038/srep00765
APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,158

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Beating Bone Marrow Cancer

To lessen the impact of chemotherapy on bone marrow cancer patients, hematologists are recruiting the patients' own immune systems to help. White. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: